YIELD10 Bioscience (YTENQ) 10-Q 13 Aug 15 2015 Q2 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	6 Months Ended
	Jun. 30, 2015	Aug. 08, 2015
Document and Entity Information
Entity registrant name	METABOLIX, INC.
Entity central index key	1,121,702
Current fiscal year end date	--12-31
Entity filer category	Smaller Reporting Company
Document type	10-Q
Document period end date	Jun. 30, 2015
Document fiscal year focus	2,015
Document fiscal period focus	Q2
Amendment flag	false
Entity common stock, shares outstanding		26,981,214
Entity current reporting status	Yes

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 22,707	$ 20,046
Accounts receivable	139	45
Due from related parties	90	112
Unbilled receivables	346	420
Inventory	555	586
Prepaid expenses and other current assets	1,631	756
Total current assets	25,468	21,965
Restricted cash	619	619
Property and equipment, net	743	456
Other assets	95	95
Total assets	26,925	23,135
Current Liabilities:
Accounts payable	384	333
Accrued expenses	3,184	3,709
Deferred revenue	246	147
Total current liabilities	3,814	4,189
Other long-term liabilities	150	150
Total liabilities	$ 3,964	$ 4,339
Commitments and contingencies (Note 9)
Stockholders’ Equity:
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding	$ 0	$ 0
Common stock ($0.01 par value per share); 250,000,000 shares authorized at June 30, 2015 and December 31, 2014; 26,959,980 and 22,530,322 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	270	225
Additional paid-in capital	336,749	320,707
Accumulated other comprehensive loss	(70)	(64)
Accumulated deficit	(313,988)	(302,072)
Total stockholders’ equity	22,961	18,796
Total liabilities and stockholders’ equity	$ 26,925	$ 23,135

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock shares authorized	250,000,000	250,000,000
Common stock, shares issued	26,959,980	22,530,322
Common stock, shares outstanding	26,959,980	22,530,322

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue:
Product revenue	$ 113	$ 211	$ 185	$ 313
Grant revenue	470	463	922	911
License fee and royalty revenue	161	25	282	88
Total revenue	744	699	1,389	1,312
Costs and expenses:
Cost of product revenue	90	420	174	586
Research and development	4,319	4,380	8,244	9,192
Selling, general, and administrative	2,464	2,665	4,930	5,797
Total costs and expenses	6,873	7,465	13,348	15,575
Loss from continuing operations	(6,129)	(6,766)	(11,959)	(14,263)
Other income (expense):
Interest income, net	1	(3)	2	2
Other income (expense), net	55	7	41	8
Total other income (expense), net	56	4	43	10
Net loss from continuing operations	(6,073)	(6,762)	(11,916)	(14,253)
Discontinued operations:
Loss from discontinued operations	0	(473)	0	(1,136)
Total loss from discontinued operations	0	(473)	0	(1,136)
Net loss	$ (6,073)	$ (7,235)	$ (11,916)	$ (15,389)
Basic and diluted net loss per share:
Net loss from continuing operations	$ (0.26)	$ (1.16)	$ (0.52)	$ (2.45)
Net loss from discontinued operations	0	(0.08)	0	(0.20)
Net loss per share	$ (0.26)	$ (1.24)	$ (0.52)	$ (2.65)
Number of shares used in per share calculations:
Basic and diluted (in shares)	23,117,539	5,831,490	22,838,511	5,816,379

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Statement of Comprehensive Income [Abstract]
Net loss:	$ (6,073)	$ (7,235)	$ (11,916)	$ (15,389)
Other comprehensive loss
Change in unrealized loss on investments	0	(1)	0	(2)
Change in foreign currency translation adjustment	(1)	(4)	(6)	(30)
Total other comprehensive loss	(1)	(5)	(6)	(32)
Comprehensive loss	$ (6,074)	$ (7,240)	$ (11,922)	$ (15,421)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities
Net loss	$ (11,916,000)	$ (15,389,000)
Loss from discontinued operation	0	(1,136,000)
Loss from continuing operations	(11,916,000)	(14,253,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	100,000	333,000
Charge for 401(k) company common stock match	218,000	259,000
Stock-based compensation	894,000	1,379,000
Inventory impairment	0	228,000
Changes in operating assets and liabilities:
Accounts receivables	(94,000)	424,000
Due from related party	22,000	51,000
Unbilled receivables	74,000	48,000
Inventory	31,000	28,000
Prepaid expenses and other assets	(875,000)	17,000
Accounts payable	(165,000)	(147,000)
Accrued expenses	(517,000)	(1,741,000)
Deferred rent and other long-term liabilities	0	(50,000)
Deferred revenue	99,000	58,000
Net cash used by continuing operations for operating activities	(12,129,000)	(13,366,000)
Net cash used by discontinued operations for operating activities	0	(480,000)
Net cash used in operating activities	(12,129,000)	(13,846,000)
Cash flows from investing activities
Purchase of property and equipment	(209,000)	(100,000)
Purchase of short-term investments	0	(1,508,000)
Proceeds from the sale and maturity of short-term investments	0	13,019,000
Net cash (used by) provided by investing activities	(209,000)	11,411,000
Cash flows from financing activities
Proceeds from options exercised	0	300,000
Proceeds from private placement offering	15,000,000	0
Net cash provided by financing activities	15,000,000	300,000
Effect of exchange rate changes on cash and cash equivalents	(1,000)	(32,000)
Net increase (decrease) in cash and cash equivalents	2,661,000	(2,167,000)
Cash and cash equivalents at beginning of period	20,046,000	7,698,000
Cash and cash equivalents at end of period	22,707,000	5,531,000
Supplemental disclosure of non-cash information:
Purchase of property and equipment included in accrued expenses	178,000	0
Private placement offering costs included in accounts payable and accrued expenses	297,000	0
Restricted stock units issued to settle incentive compensation obligation	$ 305,000	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Metabolix, Inc. (the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements have been condensed or omitted. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The consolidated financial statements, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position and results of operations for the interim periods ended June 30, 2015 and 2014 . The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for any future period or the entire fiscal year. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2014 , which are contained in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2015. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. During 2014, the Company completed the sale of substantially all of the assets of Metabolix GmbH. The consolidated condensed financial statements for the three and six month periods ended June 30, 2014, have been presented to reflect the operations of Metabolix GmbH as a discontinued operation. See Note 13 for additional information. On May 26, 2015, the Company effected a 1-for-6 reverse stock split of its common stock, as determined by the Company’s board of directors under authorization approved at a special meeting of stockholders held on October 30, 2014. Unless otherwise indicated, all share amounts, per share data, share prices, exercise prices, and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split. The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. However, with the exception of 2012, when the Company recognized $38,885 of deferred revenue from a terminated joint venture, it has recorded losses since its inception, including for the fiscal quarter ended June 30, 2015 . As of June 30, 2015 , the Company held unrestricted cash and cash equivalents of $22,707 . The Company’s present capital resources are not sufficient to fund its planned operations for a twelve month period and, therefore, raise substantial doubt about its ability to continue as a going concern. The Company was successful during its fiscal quarters ending June 30, 2015 and September 30, 2014, in raising $14,703 and $24,913 , net of offering costs, respectively, through private equity offerings. It will, however, require additional funding during the next twelve months to continue its operations and support its capital needs. The timing, structure and vehicles for obtaining future financing are under consideration, but there can be no assurance that such financing efforts will be successful. The Company intends to use the proceeds of its recent and any future financings to continue developing its specialty biopolymers business as the foundation for its longer range commercial scale plans and the future growth of its business. The Company continues to face significant challenges and uncertainties and, as a result, its available capital resources may be consumed more rapidly than currently expected due to (a) lower than expected sales of its biopolymer products as a result of slow market adoption; (b) increases in capital costs or operating expenses related to the Company's establishment, start-up, and operation of biopolymer manufacturing either on its own or with third parties; (c) changes the Company may make to the business that affect ongoing operating expenses; (d) changes the Company may make to its business strategy; (e) changes in the Company's research and development spending plans; and (f) other items affecting the Company's forecasted level of expenditures and use of cash resources. If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986 due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies, or grant licenses on terms that are not favorable to the Company. Failure to receive additional funding during the next twelve months may force the Company to delay, scale back or otherwise modify its business and manufacturing plans, sales and marketing efforts, research and development activities and other operations, and/or seek strategic alternatives. The condensed consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.

ACCOUNTING POLICIES

ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
ACCOUNTING POLICIES	ACCOUNTING POLICIES There have been no material changes in accounting policies since the Company’s fiscal year ended December 31, 2014 , as described in Note 2 to the consolidated financial statements included in its Annual Report on Form 10-K for the year then ended. Principles of Consolidation The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its German subsidiary, Metabolix GmbH, and its Canadian subsidiary, Metabolix Oilseeds, Inc. On October 20, 2014, the Company completed the sale of substantially all of the assets of Metabolix GmbH to AKRO-PLASTIC GmbH, a German manufacturer of engineering plastics compounds. The condensed consolidated financial statements for the three months and six months ended June 30, 2014, have been presented to reflect the operations of Metabolix GmbH as a discontinued operation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Foreign Currency Translation Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. At June 30, 2015 , the Company’s cash equivalents are invested solely in money market funds. The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary. At June 30, 2015 , the Company’s accounts and unbilled receivables include $420 or 73% from U.S. and Canadian government grants. At June 30, 2015 , the Company’s Renewable Enhanced Feedstocks for Advanced Biofuels and Bioproducts ("REFABB") grant from the Department of Energy represented 51% of total government grant receivables. At December 31, 2014 , the Company’s worldwide accounts and unbilled receivables include $429 or 74% from government grants. At December 31, 2014 , the Company’s REFABB grant from the Department of Energy represented 63% of total government grant receivables.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In April 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-8, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies the related disclosure requirements. Under the new guidance, a disposal of a component of an entity or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results and is disposed of or classified as held for sale. The standard also introduces several new disclosures. The guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale after the effective date. ASU 2014-8 is effective for annual and interim periods beginning after December 15, 2014, with early adoption permitted. The Company elected early adoption of ASU 2014-8 and applied the new guidance in connection with the discontinuation of its wholly-owned subsidiary, Metabolix GmbH, in 2014. See Note 13, Discontinued Operation. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In July 2015, the FASB delayed the effective date of the new revenue standard by one year. The new standard will be effective for us on January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations. In August 2014, the FASB issued an amendment that requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this update provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for one year after the date that the financial statements are issued and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently reviewing the potential impact of adopting the new guidance.

BASIC AND DILUTED NET INCOME (L

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
BASIC AND DILUTED NET INCOME (LOSS) PER SHARE	BASIC AND DILUTED NET INCOME (LOSS) PER SHARE Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net income by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, there is no difference in basic and dilutive loss per share. Common stock equivalents include stock options, restricted stock awards and warrants. The Company follows the two-class method when computing net loss per share, when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based on their respective rights to receive dividends, as if all income for the period has been distributed or losses to be allocated if they are contractually required to fund losses. There were no amounts allocated to participating securities as the Company had no outstanding shares that met the definition of participating securities at June 30, 2015. On May 26, 2015, the Company effected a 1-for-6 reverse stock split of its common stock. The calculation of basic and diluted net loss per share, as presented in the accompanying Condensed Consolidated Statements of Operations, have been determined based on retroactive adjustment of weighted average shares outstanding for all periods presented. The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the three and six months ended June 30, 2015 and 2014, respectively, are shown below: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Options 937,121 1,227,400 970,460 1,242,710 Restricted stock units 1,180,773 100,000 643,372 99,448 Warrants 648,297 — 325,939 — Total 2,766,191 1,327,400 1,939,771 1,342,158

INVENTORY

INVENTORY	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY The components of biopolymer inventories of the Company’s continuing operations are as follows: June 30, December 31, Raw materials $ 9 $ 2 Finished goods 546 584 Total inventory $ 555 $ 586 On a quarterly basis, the Company uses consistent methodologies to evaluate inventory for net realizable value, reducing the value of inventory for excess and obsolete inventory based upon certain assumptions made about future customer demand, quality and possible alternative uses. The Company did not record any inventory impairment charges during the three and six months ended June 30, 2015 . During the three and six months ended June 30, 2014, the Company recorded a $228 charge to cost of product revenue for raw material and finished goods inventory that it determined was unlikely to be sold.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The Company has certain financial assets recorded at fair value which have been classified as Level 1 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input. At June 30, 2015 and December 31, 2014, the Company did not own any Level 2 or Level 3 financial assets and there were no transfers between classification levels. The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. Fair value measurements at reporting date using Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Balance as of Description (Level 1) (Level 2) (Level 3) June 30, 2015 Cash equivalents: Money market funds $ 20,512 $ — $ — $ 20,512 Total $ 20,512 $ — $ — $ 20,512 Fair value measurements at reporting date using Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Balance as of Description (Level 1) (Level 2) (Level 3) December 31, 2014 Cash equivalents: Money market funds $ 19,011 $ — $ — $ 19,011 Total $ 19,011 $ — $ — $ 19,011

ACCRUED EXPENSES

ACCRUED EXPENSES	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	ACCRUED EXPENSES Accrued expenses consisted of the following at: June 30, December 31, Employee compensation and benefits $ 1,754 $ 2,621 Professional services 755 564 Commercial manufacturing 270 77 Other 405 447 Total accrued expenses $ 3,184 $ 3,709

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION At June 30, 2015 , there was approximately $4,534 of pre-tax stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized. Employee and Director Stock Options The Company recognized stock-based compensation expense related to employee stock option awards of $578 and $891 for the three and six months ended June 30, 2015, respectively. Stock-based compensation expense related to employee stock option awards was $594 and $1,379 for the three and six months ended June 30, 2014, respectively. The compensation expense related to unvested stock options is expected to be recognized over a remaining weighted average period of 2.37 years. A summary of option activity for the six months ended June 30, 2015 is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2014 1,110,721 $ 28.22 Granted 31,208 3.72 Exercised — — Forfeited (863 ) 7.85 Expired (209,728 ) 33.79 Outstanding at June 30, 2015 931,338 $ 26.16 Options exercisable at June 30, 2015 597,740 $ 36.09 Weighted average grant date fair value of options granted during the six months ended June 30, 2015 $ 2.68 Restricted Stock Units On January 2, 2014, the Company awarded 100,000 restricted stock units ("RSUs") to its Chief Executive Officer. These RSUs contain both market and performance conditions which are based on the achievement of certain stock price and revenue targets, respectively. The RSUs vest in various percentages over three years (subject to certain accelerated and continued vesting events) once the agreed-upon stock price and/or revenue based targets are achieved. To the extent that the market or performance conditions are not met by January 2, 2016, the RSUs will be forfeited. The Company estimated the fair value and derived service period of the awards using a Monte Carlo valuation model. The Company is recognizing compensation expense for this award over its requisite service period, which is equal to the cumulative time expected to achieve one of the triggering conditions followed by a three year post-triggering event vesting period. On April 1, 2015, the Company awarded 203,967 RSUs to members of senior management pursuant to elections previously made by the grantees to convert a portion of their 2014 performance bonuses from cash to equity. These RSUs will vest one year from the date of grant, subject to service conditions. On April 1, 2015, the Company also awarded 876,806 long-term incentive RSUs to employees. These RSUs will vest in four equal annual installments beginning one year after the date of grant, subject to service conditions. The Company records stock compensation expense for RSUs on a straight line basis over their vesting period based on the RSU's award date market value. The Company will pay required minimum income tax withholding associated with RSUs as they vest and will withhold from the common stock issuable on vesting of the RSUs a number of shares with an aggregate fair market value equal to the tax withholding amount unless the employee makes other arrangements for payment of the tax withholding. A summary of RSU activity for the six months ended June 30, 2015 is as follows: Number of RSUs Weighted Average Remaining Contractual Life (years) Outstanding at December 31, 2014 100,000 Awarded 1,080,773 Released — Forfeited — Outstanding at June 30, 2015 1,180,773 1.84 Vested and expected to vest as of June 30, 2015 997,606 1.71 Weighted average remaining recognition period 2.96 Weighted average grant date fair value of RSUs granted during the six months ended June 30, 2015 $ 3.78

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations. New Contractual Commitments In connection with the Company’s plan to increase pilot production of its PHA biopolymers, during May 2015 the Company entered into a two -year agreement with a U.S. supplier of toll fermentation services and another two -year agreement with the owner/operator of the Company’s U.S. pilot resin recovery facility. Under these manufacturing agreements, which became effective July 1, 2015, the Company estimates that it will be obligated to pay quarterly fixed service fees of approximately $1,100 after the commencement of full scale production and continuing through at least December 31, 2016. The Company made a $1,000 prepayment against future fixed service fees in May 2015. In addition to these fixed charges, the Company is obligated to pay certain variable production costs as incurred.

GEOGRAPHIC INFORMATION

GEOGRAPHIC INFORMATION	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION	GEOGRAPHIC INFORMATION The geographic distribution of the Company’s revenues and long-lived assets from continuing operations are summarized in the tables below: U.S. Canada Eliminations Total Three Months Ended June 30, 2015: Net revenues from unaffiliated customers $ 744 $ — $ — $ 744 Inter-geographic revenues — 203 (203 ) — Net revenues $ 744 $ 203 $ (203 ) $ 744 Three Months Ended June 30, 2014: Net revenues from unaffiliated customers $ 655 $ 44 $ — $ 699 Inter-geographic revenues — 183 (183 ) — Net revenues $ 655 $ 227 $ (183 ) $ 699 Six Months Ended June 30, 2015: Net revenues from unaffiliated customers $ 1,388 $ 1 $ — $ 1,389 Inter-geographic revenues — 402 (402 ) — Net revenues $ 1,388 $ 403 $ (402 ) $ 1,389 Six Months Ended June 30, 2014: Net revenues from unaffiliated customers $ 1,231 $ 81 $ — $ 1,312 Inter-geographic revenues — 361 (361 ) — Net revenues $ 1,231 $ 442 $ (361 ) $ 1,312 Foreign revenue is based on the country in which the Company’s subsidiary that earned the revenue is domiciled. During the three and six months ended June 30, 2015 , revenue earned from the Company’s REFABB grant with the U.S. Department of Energy totaled $347 and $677 , respectively, and represented 47% and 49% of total revenue. During the three and six months ended June 30, 2014, revenue earned from the Company's REFABB grant totaled $307 and $608 , respectively, and represented 44% and 46% of total revenue. During the six months ended June, 30, 2015, no product customers represented 10% or more of the Company’s total revenues. During the six months ended June 30, 2014, one customer represented 10% of the Company's total revenues. The geographic distribution of the Company’s long-lived assets is summarized as follows: U.S. Canada Eliminations Total June 30, 2015 $ 735 $ 8 $ — $ 743 December 31, 2014 $ 441 $ 15 $ — $ 456

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using future enacted tax rates. A valuation allowance is recorded against deferred tax assets if it is more likely than not that some or all of the deferred tax assets will not be realized. For the three and six months ended June 30, 2015 and 2014 , the Company did not recognize any tax expense or benefit due to its continued net operating loss position. Due to the uncertainty surrounding the realization of favorable tax attributes in future tax returns, the Company has recorded a full valuation allowance against its otherwise recognizable net deferred tax assets. The Company follows the accounting guidance related to income taxes including guidance which addresses accounting for uncertainty in income taxes. This guidance prescribes a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosures and transitions. The Company had no amounts recorded for any unrecognized tax benefits as of June 30, 2015 or December 31, 2014 .

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES The Company engaged in various transactions with Tepha, Inc., a related party, and recorded $115 and $235 of license and royalty revenue during the three months and six months ended June 30, 2015 , respectively. During the three and six months ended June 30, 2014, the Company recorded license and royalty revenue from Tepha of $25 and $68 , respectively. As of June 30, 2015 and December 31, 2014, the Company had $90 and $112 , respectively, of outstanding receivables due from Tepha for royalties.

DISCONTINUED OPERATION

DISCONTINUED OPERATION	6 Months Ended
	Jun. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATION	DISCONTINUED OPERATION The Company decided in September 2014 to discontinue its operations in Germany and sold substantially all of the assets of its wholly-owned German subsidiary, Metabolix GmbH. The Company does not expect to have significant ongoing involvement in the operations formerly conducted by Metabolix GmbH. The consolidated financial statements for the three and six months ending June 30, 2014, have been presented to reflect the operations of Metabolix GmbH as a discontinued operation. The following represent the major items comprising loss from discontinued operations for the three and six months ended June 30, 2014 . Three Months Ended June 30, Six Months Ended June 30, 2014 2014 Total revenue $ 471 $ 927 Costs and expenses: Cost of product revenue 354 883 Research and development 99 187 Selling, general and administrative 491 993 Total costs and expenses 944 2,063 Net loss $ (473 ) $ (1,136 )

CAPITAL STOCK

CAPITAL STOCK	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]
CAPITAL STOCK	CAPITAL STOCK Common and Preferred Stock Issuances On May 26, 2015, the Company effected a 1-for-6 reverse split of its common stock, as determined by the Company's board of directors under authorization approved at a special meeting of stockholders held on October 30, 2014. The reverse stock split reduced the number of shares of the Company's common stock currently outstanding at the time the reverse split was made effective from approximately 135.5 million shares to approximately 22.6 million shares. Proportional adjustments were made to the Company's outstanding stock options and restricted stock units and to the number of shares issued and issuable under the Company's equity compensation plans. The number of authorized shares of the Company's common stock remained at 250 million shares. On June 19, 2015, the Company completed a private placement of its securities. Proceeds received from the transaction were $14,703 , net of issuance costs of $297 . Investors participating in the transaction purchased a total of 4,370,000 shares of common stock at a price of $3.32 per share and warrants with a purchase price of $0.125 per warrant to purchase up to an aggregate of 3,933,000 additional shares of common stock. The warrants have a four -year term and are immediately exercisable at a price of $3.98 per share. The Company reviewed the accounting guidance for warrants and has determined that the warrants should be recorded as equity within additional paid-in capital at June 30, 2015. On August 22, 2014, the Company completed a private placement of its securities. Proceeds received from the transaction were $24,914 , net of issuance costs of $86 . Investors participating in the transaction purchased a total of 8,333,333 units of the Company’s securities at a price of $3.00 per unit. Each unit consisted of one share of the Company’s common stock and one thousandth of a share of the Company’s Series B Convertible Preferred Stock, for a total of 8,333,333 shares of common stock and 50,000 shares of Series B Convertible Preferred Stock. Each share of the preferred stock issued in the transaction was non-voting, was not redeemable, had no liquidation preference and the only conversion rights were that each share was automatically convertible into 166.67 shares of common stock upon the effectiveness of the filing by the Company of a charter amendment to increase the number of shares of authorized common stock to not less than 150,000,000 . On October 30, 2014, following stockholder approval of a charter amendment to increase the number of authorized shares of the Company’s common stock to 250,000,000 and the effectiveness of such charter amendment, each share of preferred stock issued in the private placement automatically converted into 166.67 shares of common stock, for a total of 8,333,333 additional shares of common stock.

RESTRUCTURING

RESTRUCTURING	6 Months Ended
	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
RESTRUCTURING	RESTRUCTURING In October 2014, the Company initiated a restructuring of its U.S. organization to reflect its more narrow strategic focus on PHA performance biopolymers and to modify staffing to the level the Company believed necessary to support successful implementation of its current business strategy. The scope of the restructuring also reflected the Company’s decision, consistent with its business strategy, to suspend work in its chemicals program. The Company has recognized a total of $659 in restructuring charges related to post-employment benefits. At June 30, 2015, $209 of the restructuring charges remain to be paid during 2015. Original Charges and Amounts Accrued Adjustments to Charges Amounts Paid through June 30, 2015 Amounts Accrued at June 30, 2015 Employee severance, benefits and related costs $ 624 $ 35 $ (450 ) $ 209 $ 624 $ 35 $ (450 ) $ 209

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Principles of consolidation	Principles of Consolidation The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its German subsidiary, Metabolix GmbH, and its Canadian subsidiary, Metabolix Oilseeds, Inc. On October 20, 2014, the Company completed the sale of substantially all of the assets of Metabolix GmbH to AKRO-PLASTIC GmbH, a German manufacturer of engineering plastics compounds. The condensed consolidated financial statements for the three months and six months ended June 30, 2014, have been presented to reflect the operations of Metabolix GmbH as a discontinued operation.
Use of estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America ("GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Foreign currency translation	Foreign Currency Translation Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiaries are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.
Concentration of credit risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments, when purchased, are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer. At June 30, 2015 , the Company’s cash equivalents are invested solely in money market funds. The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary.
Recent accounting pronouncements	RECENT ACCOUNTING PRONOUNCEMENTS In April 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-8, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, which changes the criteria for determining which disposals can be presented as discontinued operations and modifies the related disclosure requirements. Under the new guidance, a disposal of a component of an entity or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results and is disposed of or classified as held for sale. The standard also introduces several new disclosures. The guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale after the effective date. ASU 2014-8 is effective for annual and interim periods beginning after December 15, 2014, with early adoption permitted. The Company elected early adoption of ASU 2014-8 and applied the new guidance in connection with the discontinuation of its wholly-owned subsidiary, Metabolix GmbH, in 2014. See Note 13, Discontinued Operation. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In July 2015, the FASB delayed the effective date of the new revenue standard by one year. The new standard will be effective for us on January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations. In August 2014, the FASB issued an amendment that requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. The amendments in this update provide guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern for one year after the date that the financial statements are issued and to provide related footnote disclosures. In doing so, the amendments should reduce diversity in the timing and content of footnote disclosures. The amendments in this update apply to all entities and are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently reviewing the potential impact of adopting the new guidance.

BASIC AND DILUTED NET INCOME 23

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of number of shares of potentially dilutive common stock related to options and warrants that were excluded from the calculation of dilutive shares	The number of shares of potentially dilutive common stock presented on a weighted average basis, related to options, restricted stock units and warrants (prior to consideration of the treasury stock method) that were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive for the three and six months ended June 30, 2015 and 2014, respectively, are shown below: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Options 937,121 1,227,400 970,460 1,242,710 Restricted stock units 1,180,773 100,000 643,372 99,448 Warrants 648,297 — 325,939 — Total 2,766,191 1,327,400 1,939,771 1,342,158

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Jun. 30, 2015
Inventory Disclosure [Abstract]
Schedule of the components of the Company's biopolymer inventories	The components of biopolymer inventories of the Company’s continuing operations are as follows: June 30, December 31, Raw materials $ 9 $ 2 Finished goods 546 584 Total inventory $ 555 $ 586

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Schedule of information about assets that are measured at fair value on a recurring basis	The tables below present information about the Company’s assets that are measured at fair value on a recurring basis as of June 30, 2015 and December 31, 2014 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value. Fair value measurements at reporting date using Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Balance as of Description (Level 1) (Level 2) (Level 3) June 30, 2015 Cash equivalents: Money market funds $ 20,512 $ — $ — $ 20,512 Total $ 20,512 $ — $ — $ 20,512 Fair value measurements at reporting date using Quoted prices in active markets for identical assets Significant other observable inputs Significant unobservable inputs Balance as of Description (Level 1) (Level 2) (Level 3) December 31, 2014 Cash equivalents: Money market funds $ 19,011 $ — $ — $ 19,011 Total $ 19,011 $ — $ — $ 19,011

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	6 Months Ended
	Jun. 30, 2015
Payables and Accruals [Abstract]
Schedule of accrued expenses	Accrued expenses consisted of the following at: June 30, December 31, Employee compensation and benefits $ 1,754 $ 2,621 Professional services 755 564 Commercial manufacturing 270 77 Other 405 447 Total accrued expenses $ 3,184 $ 3,709

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of option activity	A summary of option activity for the six months ended June 30, 2015 is as follows: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2014 1,110,721 $ 28.22 Granted 31,208 3.72 Exercised — — Forfeited (863 ) 7.85 Expired (209,728 ) 33.79 Outstanding at June 30, 2015 931,338 $ 26.16 Options exercisable at June 30, 2015 597,740 $ 36.09 Weighted average grant date fair value of options granted during the six months ended June 30, 2015 $ 2.68
Schedule of restricted stock units activity	A summary of RSU activity for the six months ended June 30, 2015 is as follows: Number of RSUs Weighted Average Remaining Contractual Life (years) Outstanding at December 31, 2014 100,000 Awarded 1,080,773 Released — Forfeited — Outstanding at June 30, 2015 1,180,773 1.84 Vested and expected to vest as of June 30, 2015 997,606 1.71 Weighted average remaining recognition period 2.96 Weighted average grant date fair value of RSUs granted during the six months ended June 30, 2015 $ 3.78

GEOGRAPHIC INFORMATION (Tables)

GEOGRAPHIC INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2015
Segment Reporting [Abstract]
Schedule of the geographic distribution of revenues and long-lived assets from continuing operations	The geographic distribution of the Company’s revenues and long-lived assets from continuing operations are summarized in the tables below: U.S. Canada Eliminations Total Three Months Ended June 30, 2015: Net revenues from unaffiliated customers $ 744 $ — $ — $ 744 Inter-geographic revenues — 203 (203 ) — Net revenues $ 744 $ 203 $ (203 ) $ 744 Three Months Ended June 30, 2014: Net revenues from unaffiliated customers $ 655 $ 44 $ — $ 699 Inter-geographic revenues — 183 (183 ) — Net revenues $ 655 $ 227 $ (183 ) $ 699 Six Months Ended June 30, 2015: Net revenues from unaffiliated customers $ 1,388 $ 1 $ — $ 1,389 Inter-geographic revenues — 402 (402 ) — Net revenues $ 1,388 $ 403 $ (402 ) $ 1,389 Six Months Ended June 30, 2014: Net revenues from unaffiliated customers $ 1,231 $ 81 $ — $ 1,312 Inter-geographic revenues — 361 (361 ) — Net revenues $ 1,231 $ 442 $ (361 ) $ 1,312
Schedule of the geographic distribution of long-lived assets	The geographic distribution of the Company’s long-lived assets is summarized as follows: U.S. Canada Eliminations Total June 30, 2015 $ 735 $ 8 $ — $ 743 December 31, 2014 $ 441 $ 15 $ — $ 456

DISCONTINUED OPERATION (Tables)

DISCONTINUED OPERATION (Tables)	6 Months Ended
	Jun. 30, 2015
Discontinued Operations and Disposal Groups [Abstract]
Schedule of discontinued operations income statement	The following represent the major items comprising loss from discontinued operations for the three and six months ended June 30, 2014 . Three Months Ended June 30, Six Months Ended June 30, 2014 2014 Total revenue $ 471 $ 927 Costs and expenses: Cost of product revenue 354 883 Research and development 99 187 Selling, general and administrative 491 993 Total costs and expenses 944 2,063 Net loss $ (473 ) $ (1,136 )

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	6 Months Ended
	Jun. 30, 2015
Restructuring and Related Activities [Abstract]
Schedule of accrued restructuring charges	Original Charges and Amounts Accrued Adjustments to Charges Amounts Paid through June 30, 2015 Amounts Accrued at June 30, 2015 Employee severance, benefits and related costs $ 624 $ 35 $ (450 ) $ 209 $ 624 $ 35 $ (450 ) $ 209

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) - USD ($)	Jun. 19, 2015	Aug. 22, 2014	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred revenue recognized from the terminated Telles joint venture							$ 38,885,000
Unrestricted cash, cash equivalents and investments			$ 22,707,000		$ 22,707,000
Period over which company's present capital resources are not sufficient to fund its planned operations					12 months
Proceeds from private placement offering	$ 14,703,000	$ 24,914,000	$ 14,703	$ 24,913,000	$ 15,000,000	$ 0

ACCOUNTING POLICIES (Details)

ACCOUNTING POLICIES (Details) - Accounts receivable - Credit concentration risk - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
US, Canadian, and German government grants
Concentration of credit risk
Accounts receivable	$ 420
Receivables/Sales (as a percent)	73.00%
Government grants
Concentration of credit risk
Accounts receivable		$ 429
Receivables/Sales (as a percent)		74.00%
Development of renewable enhanced feedstocks for advanced biofuels and bioproducts department of energy grant
Concentration of credit risk
Receivables/Sales (as a percent)	51.00%	63.00%

BASIC AND DILUTED NET INCOME 33

BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	2,766,191	1,327,400	1,939,771	1,342,158
Options
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	937,120.84	1,227,400	970,460	1,242,710
Restricted stock units
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	1,180,773	100,000	643,372	99,447.5
Warrants
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	648,297	0	325,939	0

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials					$ 9	$ 2
Finished goods					546	584
Total inventory					$ 555	$ 586
Charges to cost of product revenue for inventory unlikely to be sold	$ 0	$ 228	$ 0	$ 228

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Fair Value, measurements, recurring - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Fair value measurements
Total	$ 20,512	$ 19,011
Money market funds
Fair value measurements
Cash equivalents	20,512	19,011
Quoted prices in active markets for identical assets
Fair value measurements
Total	20,512	19,011
Quoted prices in active markets for identical assets | Money market funds
Fair value measurements
Cash equivalents	$ 20,512	$ 19,011

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 1,754		$ 2,621
Professional services	755		564
Commercial manufacturing	270		77
Other	405		447
Total accrued expenses	$ 3,184	$ 3,184	$ 3,709

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee stock option
Stock-based compensation
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized	$ 4,534		$ 4,534
Stock-based compensation expense	$ 578	$ 594	$ 891	$ 1,379
Weighted average remaining recognition period			2 years 4 months 15 days
Options
Stock Options, Number of Shares [Roll Forward]
Outstanding at the beginning of the period (in shares)			1,110,721
Granted (in shares)			31,208
Exercised (in shares)			0
Forfeited (in shares)			(863)
Expired (in shares)			(209,728)
Outstanding at the end of the period (in shares)	931,338		931,338
Options exercisable at the end of the period (in shares)	597,740		597,740
Stock Options, Weighted Average Exercise Price [Roll Forward]
Outstanding at the beginning of the period (in dollars per share)			$ 28.22
Granted (in dollars per share)			3.72
Exercised (in dollars per share)			0
Forfeited (in dollars per share)			7.85
Expired (in dollars per share)			33.79
Outstanding at the end of the period (in dollars per share)	$ 26.16		26.16
Options exercisable at the end of the period (in dollars per share)	$ 36.09		36.09
Weighted average grant date fair value of options granted (in dollars per share)			$ 2.68

STOCK-BASED COMPENSATION - REST

STOCK-BASED COMPENSATION - RESTRICTED STOCK UNIT ACTIVITY TABLE (Details) - Restricted Stock Units (RSUs) [Member]	Apr. 01, 2015shares	Jan. 02, 2014shares	Jun. 30, 2015item$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at December 31, 2014 (in shares)			100,000
Awarded (in shares)			1,080,773
Released (in shares)			0
Forfeited (in shares)			0
Outstanding at June 30, 2015 (in shares)			1,180,773
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted Average Remaining Contractual Life (years)			1 year 10 months 4 days
Ending vested and expected to vest (in shares)			997,606
Ending vested and expected to vest - Weighted average remaining contractual life			1 year 8 months 17 days
Weighted average remaining recognition period			2 years 11 months 15 days
Weighted average grant date fair value of RSUs granted during the six months ended June 30, 2015 | $ / shares			$ 3.78
Chief Executive Officer [Member]
Stock-based compensation
Vesting period		3 years
Number of triggering conditions | item			1
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded (in shares)		100,000
Executive Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded (in shares)	203,967
Non-Executive Employees [Member]
Stock-based compensation
Vesting period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded (in shares)	876,806

COMMITMENTS AND CONTINGENCIES C

COMMITMENTS AND CONTINGENCIES Commitments and Contingencies (Details) - New Contractual Commitment - USD ($) $ in Thousands	1 Months Ended
	May. 31, 2015	Jul. 01, 2015
Other Commitments [Line Items]
Quarterly fixed service fee		$ 1,100
Prepayment against future fixed service fees	$ 1,000
U.S. Supplier of Toll Fermentation Services
Other Commitments [Line Items]
Term of contractual service agreement	2 years
Owner/Operator of U.S. Pilot Resin Recovery Facility
Other Commitments [Line Items]
Term of contractual service agreement	2 years

GEOGRAPHIC INFORMATION - Schedu

GEOGRAPHIC INFORMATION - Schedule of distribution of revenues and long-lived assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Geographic Information
Revenue	$ 744	$ 699	$ 1,389	$ 1,312
U.S.
Geographic Information
Revenue	744	655	1,388	1,231
Canada
Geographic Information
Revenue	203	227	403	442
Operating segments
Geographic Information
Revenue	744	699
Operating segments | U.S.
Geographic Information
Revenue	744	655	1,388	1,231
Operating segments | Canada
Geographic Information
Revenue	0	44	1	81
Inter-geographic revenues | Canada
Geographic Information
Revenue	203	183
Intersegment eliminations
Geographic Information
Revenue	$ (203)	$ (183)	(402)	(361)
Intersegment eliminations | Canada
Geographic Information
Revenue			$ 402	$ 361

GEOGRAPHIC INFORMATION - Sche41

GEOGRAPHIC INFORMATION - Schedule of geographic distribution (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Geographic Information
Long-lived assets	$ 743	$ 743	$ 456
U.S.
Geographic Information
Long-lived assets	735		441
Canada
Geographic Information
Long-lived assets	$ 8		$ 15

GEOGRAPHIC INFORMATION (Narrati

GEOGRAPHIC INFORMATION (Narrative) (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
Concentration risk
Revenue earned from the REFABB grant	$ 470	$ 463	$ 922	$ 911
US Department of energy | Sales
Concentration risk
Revenue earned from the REFABB grant	$ 347	$ 307	$ 677	$ 608
Concentration risk (as a percent)	47.00%	44.00%	49.00%	46.00%
Customer one | Sales
Concentration risk
Concentration risk (as a percent)			10.00%
Number of customers			0	1

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Unrecognized tax benefits	$ 0	$ 0

RELATED PARTIES (Details)

RELATED PARTIES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
Related party transactions
Due from related parties					$ 90	$ 112
Tepha Inc | License revenue | Affiliated entity
Related party transactions
Revenue from related parties	$ 115	$ 25	$ 235	$ 68
Due from related parties	$ 90		$ 90			$ 112

DISCONTINUED OPERATION (Details

DISCONTINUED OPERATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net loss	$ 0	$ (473)	$ 0	$ (1,136)
Metabolix GmbH
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue		471		927
Cost of product revenue		354		883
Research and development		99		187
Selling, general and administrative		491		993
Total costs and expenses		944		2,063
Net loss		$ (473)		$ (1,136)

CAPITAL STOCK (Details)

CAPITAL STOCK (Details)	Jun. 19, 2015USD ($)shares$ / shares$ / warrant	May. 26, 2015shares	Oct. 30, 2014shares	Aug. 22, 2014USD ($)shares$ / warrant	Jun. 30, 2015USD ($)shares	Dec. 31, 2014USD ($)shares	Jun. 30, 2015USD ($)shares	Jun. 30, 2014USD ($)	May. 25, 2015shares
Common Stock Issuances
Common stock, shares outstanding		22,600,000			26,959,980	22,530,322	26,959,980		135,500,000
Proceeds from private placement offering | $	$ 14,703,000			$ 24,914,000	$ 14,703	$ 24,913,000	$ 15,000,000	$ 0
Common stock shares authorized		250,000,000			250,000,000	250,000,000	250,000,000
Issuance costs from private placement | $	$ 297,000			$ 86,000
Number of units purchased				8,333,333
Unit price (in dollars per share) | $ / warrant	0.125			3
Class of Warrant or Right Expiration Term	4 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 3.98
Common stock, shares issued				8,333,333	26,959,980	22,530,322	26,959,980
Preferred shares issued				50,000	0	0	0
Common stock conversion ratio for each preferred stock		0.1667
Restricted stock units
Common Stock Issuances
Number of series B convertible preferred stock shares in each unit for purchase				0.001
Common stock conversion ratio for each preferred stock			166.67	166.67
Common stock
Common Stock Issuances
Common stock shares authorized			250,000,000	150,000,000
Number of units purchased	4,370,000
Share Price | $ / shares	$ 3.32
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	3,933,000
Number of common stock shares included in each unit for purchase				1
Convertible Preferred Stock, Shares Issued upon Conversion			8,333,333

RESTRUCTURING (Details)

RESTRUCTURING (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Dec. 31, 2014	Jun. 30, 2015
Restructuring Reserve [Roll Forward]
Original Charges and Amounts Accrued		$ 624
Adjustments to Charges		35
Amounts Paid through June 30, 2015		(450)
Amounts Accrued at June 30, 2015	$ 624	209
Employee severance, benefits and related costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	659
Restructuring Reserve [Roll Forward]
Original Charges and Amounts Accrued		624
Adjustments to Charges		35
Amounts Paid through June 30, 2015		(450)
Amounts Accrued at June 30, 2015	$ 624	$ 209